This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (24)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Review of 37 Cases

Anton M. S. Melnyk, MD; Kim Solez, MD, FRCPC; Carl M. Kjellstrand, MD, PhD, FRCPC

Arch Intern Med. 1995;155(19):2077-2084.

Abstract
Background
Adult hemolytic-uremic syndrome is a serious, poorly understood disease with a high and variable mortality. We studied several demographic, clinical, and treatment variables, related them to outcome, and developed a new classification.

Methods
We analyzed data from 37 patients admitted from 1981 to 1991 who fulfilled four criteria (age >16 years, microangiopathic hemolytic anemia, creatinine level >150 µmol/L [>1.7 mg/dL], and no artificial heart valve). Three outcome variables were studied (survival vs death, recurrence vs no recurrence, and chronic renal failure vs no chronic renal failure).

Results
Eleven (30%) of the patients died, 10 (27%) needed dialysis, five (14%) developed chronic renal failure, and nine (24%) had recurrent episodes. Patients who presented with colitis did not die or have recurrences, but they developed chronic renal failure as often as other patients. Patients with hemolytic-uremic syndrome secondary to other diseases had the worst survival and the most recurrences. Those without any triggering factor (primary cases) were in between. In multivariate analysis, hemolytic-uremic syndrome secondary to colitis, a higher white blood cell count at admission, and a high maximum mean arterial pressure were associated with good survival prognosis.

Conclusions
The persistence of the trigger of adult hemolytic-uremic syndrome sets the stage for outcome. If the trigger is transient (such as Escherichia coli colitis), the disease will not recur and is rarely lethal. If no trigger is apparent (primary hemolytic-uremic syndrome) or the trigger persists (systemic lupus erythematosus and cancer), the syndrome has a high mortality and often recurs. We suggest a new classification: (1) extrinsic hemolytic-uremic syndrome: (a) toxic, (b) infectious; (2) intrinsic hemolytic-uremic syndrome: (a) primary, (b) secondary. The use of this classification, combined with simple data obtained at presentation and a further division of the cause as transient or persistent and irreversible, may improve the selection of therapy.

(Arch Intern Med. 1995;155:2077-2084)

Author Affiliations
From the Departments of Medicine (Drs Melnyk and Kjellstrand) and Pathology (Dr Solez), University of Alberta, Edmonton.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Gemcitabine-induced thrombotic microangiopathy: a systematic review
Izzedine et al.
Nephrol Dial Transplant 2006;21:3038-3045.
FULL TEXT  

Postdiarrheal Shiga Toxin-Mediated Hemolytic Uremic Syndrome
Siegler
JAMA 2003;290:1379-1381.
FULL TEXT  

Hemolytic-Uremic Syndrome in Adolescents
Siegler et al.
Arch Pediatr Adolesc Med 1997;151:165-169.
ABSTRACT